- Ophthalmic drugs, used to treat eye conditions such as glaucoma, dry eye disease, conjunctivitis, and macular degeneration, are increasingly vital components of modern eye care due to their effectiveness, ease of administration, and targeted drug delivery methods in both hospital and homecare settings
- The escalating demand for ophthalmic drugs is primarily fueled by the rising prevalence of eye disorders, aging populations, increased screen time leading to digital eye strain, and technological advancements in ophthalmic formulations and delivery systems
- North America dominated the ophthalmic drugs market with the largest revenue share of 41.8% in 2024, characterized by high healthcare spending, advanced diagnostic infrastructure, and the strong presence of key pharmaceutical players
- Asia-Pacific is expected to be the fastest-growing region in the ophthalmic drugs market during the forecast period with a CAGR of 7.6%, driven by a rising elderly population, increasing urbanization, greater access to healthcare, and the growing burden of diabetes-related eye disorders in countries such as China and India
- Anti-glaucoma drugs dominated the ophthalmic drugs market with a market share of 38.9% in 2024, driven by the high global incidence of glaucoma, especially among the aging population, and the availability of multiple effective drug classes such as prostaglandin analogs and beta-blockers. Combination therapies and preservative-free formulations are further enhancing segment growth
